Comparative Characterization of Canine and Human Mesenchymal Stem Cells Derived from Bone Marrow

Bertolo, Alessandro

doi:10.23937/2469-570x/1410005

Cited by 4 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this sense, hADSCs appeared to have a superior adipogenic potential on the basis of a greater number of positively stained lipid vacuoles, compared with the canine MSCs. These results are consistent with those described by others, where few and small lipid vacuoles were observable following adipose differentiation of canine MSCs [36,37]. Nevertheless, classical histochemical staining for detecting adipose differentiation has to be considered in parallel to the measurement of genic expression markers.…”

Section: Discussionsupporting

confidence: 92%

Therapeutic Potential of Autologous Adipose-Derived Stem Cells for the Treatment of Liver Disease

Gardin

Ferroni

Bellin

et al. 2018

IJMS

View full text Add to dashboard Cite

Currently, the most effective therapy for liver diseases is liver transplantation, but its use is limited by organ donor shortage, economic reasons, and the requirement for lifelong immunosuppression. Mesenchymal stem cell (MSC) transplantation represents a promising alternative for treating liver pathologies in both human and veterinary medicine. Interestingly, these pathologies appear with a common clinical and pathological profile in the human and canine species; as a consequence, dogs may be a spontaneous model for clinical investigations in humans. The aim of this work was to characterize canine adipose-derived MSCs (cADSCs) and compare them to their human counterpart (hADSCs) in order to support the application of the canine model in cell-based therapy of liver diseases. Both cADSCs and hADSCs were successfully isolated from adipose tissue samples. The two cell populations shared a common fibroblast-like morphology, expression of stemness surface markers, and proliferation rate. When examining multilineage differentiation abilities, cADSCs showed lower adipogenic potential and higher osteogenic differentiation than human cells. Both cell populations retained high viability when kept in PBS at controlled temperature and up to 72 h, indicating the possibility of short-term storage and transportation. In addition, we evaluated the efficacy of autologous ADSCs transplantation in dogs with liver diseases. All animals exhibited significantly improved liver function, as evidenced by lower liver biomarkers levels measured after cells transplantation and evaluation of cytological specimens. These beneficial effects seem to be related to the immunomodulatory properties of stem cells. We therefore believe that such an approach could be a starting point for translating the results to the human clinical practice in future.

show abstract

Section: Discussionsupporting

confidence: 92%

Therapeutic Potential of Autologous Adipose-Derived Stem Cells for the Treatment of Liver Disease

Gardin

Ferroni

Bellin

et al. 2018

IJMS

View full text Add to dashboard Cite

show abstract

“…Allogeneic and xenogeneic MSCs are a more attractive source than the autologous MSCs which have to be harvested from the tissue of each patient and put into culture before being available. Xenogeneic MSCs are an interesting alternative for use in dogs since canine MSCs have culture and upscaling limitations caused by senescence earlier in the culture process than for example in human and equine MSCs [9,10,11].…”

Section: Introductionmentioning

confidence: 99%

Scintigraphic Tracking of 99mTechnetium Labelled Equine Peripheral Blood-Derived Mesenchymal Stem Cells After Intravenous, Intramuscular and Subcutaneous Injection in Healthy Dogs.

Beerts

Brondeel

Pauwelyn

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Mesenchymal stem cell treatments in dogs have been investigated as a potential innovative alternative to current conventional therapies for a variety of conditions. So far, the precise mode of action of the MSCs has yet to be determined. The aim of this study was to gain more insights in the pharmacokinetics of MSCs by evaluating their biodistribution in healthy dogs after different injection routes.Methods: Three different studies were performed in healthy dogs to evaluate the biodistribution of radiolabelled equine peripheral blood-derived mesenchymal stem cells following intravenous, intramuscular and subcutaneous administration in comparison with free 99mTechnetium. The labelling of the equine peripheral blood-derived mesenchymal stem cells was performed using stannous chloride as reducing agent. Whole body scans were obtained using a gamma camera during a 24h follow-up.Results: The labelling efficiency ranged between 59.58 and 83.82%. Free 99mTechnetium accumulation was predominantly observed in stomach, thyroid, bladder and salivary glands while, following intravenous injection, the 99mTechnetium labelled equine peripheral blood-derived mesenchymal stem cells majorly accumulated in the liver throughout the follow-up period. After intramuscular and subcutaneous injection, the injected dose percentage remained very high at the injection site.Conclusions: A distinct difference was noted in biodistribution of the radiolabelled equine peripheral blood-derived mesenchymal stem cells compared to free 99mTechnetium indicating equine peripheral blood-derived mesenchymal stem cells have a specific pharmacokinetic pattern after systemic administration in healthy dogs. Furthermore, the natural biodistribution pattern of the used equine peripheral blood-derived mesenchymal stem cells appeared to be different to previously reported experiments using different sources of mesenchymal stem cells.

show abstract

Comparison of Canine and Feline Adipose-Derived Mesenchymal Stem Cells/Medicinal Signaling Cells With Regard to Cell Surface Marker Expression, Viability, Proliferation, and Differentiation Potential

2021

View full text Add to dashboard Cite

Remarkable immunomodulatory abilities of mesenchymal stem cells, also called multipotent mesenchymal stromal cells or medicinal signaling cells (MSCs), have entailed significant advances in veterinary regenerative medicine in recent years. Despite positive outcomes from MSC therapies in various diseases in dogs and cats, differences in MSC characteristics between small animal veterinary patients are not well-known. We performed a comparative study of cells' surface marker expression, viability, proliferation, and differentiation capacity of adipose-derived MSCs (ADMSCs) from dogs and domestic cats. The same growth media and methods were used to isolate, characterize, and culture canine and feline ADMSCs. Adipose tissue was collected from 11 dogs and 8 cats of both sexes. The expression of surface markers CD44, CD90, and CD34 was detected by flow cytometry. Viability at passage 3 was measured with the hemocytometer and compared to the viability measured by flow cytometry after 1 day of handling. The proliferation potential of MSCs was measured by calculating cell doubling and cell doubling time from second to eighth passage. Differentiation potential was determined at early and late passages by inducing cells toward adipogenic, osteogenic, and chondrogenic differentiation using commercial media. Our study shows that the percentage of CD44+CD90+ and CD34−/− cells is higher in cells from dogs than in cells from cats. The viability of cells measured by two different methods at passage 3 differed between the species, and finally, canine ADMSCs possess greater proliferation and differentiation potential in comparison to the feline ADMSCs.

show abstract

Comparative Characterization of Canine and Human Mesenchymal Stem Cells Derived from Bone Marrow

Cited by 4 publications

References 22 publications

Therapeutic Potential of Autologous Adipose-Derived Stem Cells for the Treatment of Liver Disease

Therapeutic Potential of Autologous Adipose-Derived Stem Cells for the Treatment of Liver Disease

Scintigraphic Tracking of 99mTechnetium Labelled Equine Peripheral Blood-Derived Mesenchymal Stem Cells After Intravenous, Intramuscular and Subcutaneous Injection in Healthy Dogs.

Comparison of Canine and Feline Adipose-Derived Mesenchymal Stem Cells/Medicinal Signaling Cells With Regard to Cell Surface Marker Expression, Viability, Proliferation, and Differentiation Potential

Contact Info

Product

Resources

About